<DOC>
	<DOC>NCT02963649</DOC>
	<brief_summary>To assess the safety and efficacy of the paclitaxel drug-eluting balloon IN.PACT 014 versus conventional percutaneous transluminal angioplasty (PTA) for the treatment of patients with chronic total occlusions in the infrapopliteal arteries.</brief_summary>
	<brief_title>IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1. Age ≥18 years and ≤85 years. 2. Subject has been informed of the nature of the study, agrees to participate and has signed an EC approved consent form. 3. Female subjects of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation; 4. Subject has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Clinical Category 4 or 5 . 5. Life expectancy &gt;1 year in the Investigator's opinion. 6. Reference Vessel Diameter (RVD) 2 4 mm, based on visual estimation. 7. Presence of documented runoff to the foot 8. Inflow free from flowlimiting lesion confirmed by angiography. 9. Successful predilatation of the (entire) target lesion. 1. Subject unwilling or unlikely to comply to the appropriate followup times for the duration of the study. 2. Prior stent(s) or bypass surgery within the target vessel(s) (including stents placed within target vessels during the index procedure prior to randomization. 3. Previous PTA of the target vessel within 12 months prior to index procedure. 4. Aneurysm in the target vessel. 5. Angiographic evidence of thrombus within target limb. 6. Recent MI or stroke &lt; 30 days prior to the index procedure. 7. Heart failure with Ejection Fraction &lt; 30%. 8. Impaired renal function (GFR &lt;30 mL/min) and patients on dialysis. 9. Subject with vasculitis, systemic Lupus Erythematosus or Polymyalgia Rheumatica. 10. Patient receiving systemic corticosteroid therapy. 11. Inability to tolerate concomitant antiplatelet therapy on top of oral anticoagulation therapy 12. Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/antiplatelet therapies which could not be substituted, and/or paclitaxel or an allergy to contrast media that cannot be adequately pretreated prior to the index procedure. 13. The patient is currently enrolled in another investigational device or drug trial that is interfering with the endpoints of this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug-eluting angioplasty balloon, Drug coated angioplasty balloon, Experimental, percutaneous transluminal angioplasty (PTA)</keyword>
</DOC>